Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jun;41(6):546-550.
doi: 10.1002/phar.2524. Epub 2021 Apr 27.

Use of Remdesivir in Myasthenia gravis and COVID-19

Bradley J Peters  1 , Alejandro A Rabinstein  2 , Hilary M DuBrock  3   4
Affiliations
Case Reports

Use of Remdesivir in Myasthenia gravis and COVID-19

Bradley J Peters et al. Pharmacotherapy. 2021 Jun.

Abstract

Myasthenia gravis and the associated pharmacologic management options could place patients at higher risk of contracting severe acute respiratory syndrome coronavirus 2 and exhibiting more severe manifestations of the novel coronavirus disease 2019 (COVID-19). Multiple agents have been studied for the management of the COVID-19, including remdesivir. To date, no published reports have evaluated the utilization of the antiviral remdesivir in patients with myasthenia gravis. We describe the first reported clinical course of three patients with myasthenia gravis who safely received remdesivir in combination with dexamethasone for the management of COVID-19.

Keywords: COVID; COVID-19; Myasthenia gravis; Remdesivir; SARS; coronavirus.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to report.

Similar articles

See all similar articles

Cited by

References

    1. Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375:2570‐2581. 10.1056/NEJMra1602678. - DOI - PubMed
    1. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis. Neurology. 2016;87:419‐425. 10.1212/WNL.0000000000002790. - DOI - PMC - PubMed
    1. International MG/COVID‐19 Working Group ; Jacob S, Muppidi S, et al. Guidance for the management of myasthenia gravis and Lambert‐Eaton myasthenic syndrome during COVID‐19 pandemic. J Neurol Sci. 2020;412: 116803. 10.1016/j.jns.2020.116803. - DOI - PMC - PubMed
    1. Solé G, Salort‐Campana E, Pereon Y,, et al. Guidance for the care of neuromuscular patients during the COVID‐19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network. Rev Neurol (Paris). 2020;176:507‐515. 10.1016/j.neurol.2020.04.004. - DOI - PMC - PubMed
    1. Wittbrodt ET. Drugs and Myasthenia gravis: an update. Arch Intern Med. 1997;157:399‐408. - PubMed

Publication types